Intense Pulsed Light in Meibomian Gland Dysfunctions

Completed

• Conditions: Meibomian Gland Dysfunction; Dry Eye Syndromes
• Interventions: Device: intense pulsed light (usual practice)

• Registration Number: NCT04147962
• Lead Sponsor: Centre Hospitalier Universitaire de Saint Etienne

Brief Summary

Dry eye disease (DED) is an extremely common disease whose meibomian gland dysfunction is the main etiology.

Polychromatic intense pulsed light (IPL) is a promising new therapeutic alternative but few clinical data have been published.

A new IPL device has recently been marketed: LACRYSTIM (QUANTEL, France). The investigators have been using it in our clinical practice since June 2019.

The investigators present a retrospective study on our first clinical results.

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-10
• Study Start: 2019-10-25
• Study First Submitted: 2019-10-25
• Study First Submitted QC: 2019-10-31
• Study First Posted: 2019-11-01
• Primary Completion: 2020-06-01
• Study Completion: 2020-06-01
• Last Update Submitted: 2022-05-12
• Last Update Posted: 2022-05-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 45

Inclusion Criteria

• Patients with Dry eye disease with meibomian gland dysfunction, preferentially mild to moderate, and having benefited from intense pulsed light treatment.
• patient affiliated with a social security organization

Exclusion Criteria

• patient with incomplete follow-up

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Patients with dry eye disease with meibomian gland dysfunction	intense pulsed light (usual practice)	Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations). - parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light

Primary Outcome Measures

Name	Time	Method
Lacrydiag in current clinical practice	6 months	The LacryDiag ocular surface analyzer is used for the diagnosis of dry eyes.

Secondary Outcome Measures

Name	Time	Method
collection of adverse events	6 months	-data concerning the safety: presence or absence of adverse events during treatment or afterwards (burns, tingling, redness of skin ...)
Ocular Surface Disease Index questionnaire	6 months	measured in current clinical practice. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers.
Slit lamp Photography x16 and x25	6 months	in current clinical practice
Oxford Score	6 months	measured in current clinical practice. The Oxford score is used to assess epithelial damage to the cornea and conjunctiva.
Break-up time Test	6 months	measured in current clinical practice. The measurement of the tear film rupture time determines the stability of the tear film, i.e. the degree of humidification of the eyes.
Schirmer Test	6 months	measured in current clinical practice. Determination of the quantity of tears produced.

Trial Locations

Locations (1)

CHU de Saint Etienne; 🇫🇷 Saint Etienne, France